Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2022 Dec;24(12):1238-1244.
doi: 10.1177/1098612X221074924. Epub 2022 Feb 8.

Cabergoline treatment in cats with diabetes mellitus and hypersomatotropism

Diego D Miceli  1   2 , Jorge D García  1 , Gustavo A Pompili  1 , Juan P Rey Amunategui  2 , Sergio Ferraris  2 , Omar P Pignataro  3 , Mirtha Guitelman  4
Affiliations

Cabergoline treatment in cats with diabetes mellitus and hypersomatotropism

Diego D Miceli et al. J Feline Med Surg. 2022 Dec.

Abstract

Objectives: The aim of this study was to evaluate the safety and efficacy of cabergoline to control hypersomatotropism (HST) and diabetes mellitus (DM) in cats.

Methods: This was a prospective cohort study. Twenty-three cats with HST and concurrent DM were enrolled. Cats received a dose of 10 μg/kg cabergoline q48h PO for 6 months. Serum insulin-like growth factor 1 (IGF-1) and fructosamine concentrations, insulin dose and Insulin Resistance Index (IRI) were measured at the time of diagnosis of HST and at the start of cabergoline treatment (t0), and 3 months (t1) and 6 months (t2) during cabergoline treatment.

Results: A decrease and normalization of serum IGF-1 concentration was observed in 35% and 26% of cats, respectively. Median IGF-1 (t0: 1350 ng/ml [range 832-1501]; t1: 1284 ng/ml [range 365-1501]; t2: 1240 ng/ml [range 263-1501]; P = 0.016) decreased significantly. Twelve cats underwent diagnostic imaging of the pituitary area. The median pituitary height at t0 of cats that experienced an IGF-1 reduction (n = 5/12) was significantly lower compared with those that did not experience an IGF-1 reduction (n = 7/12) (3.2 mm [range 3.1-3.7] vs 6 mm [range 3.5-9.5]; P = 0.011). Median fructosamine (t0: 628 µmol/l [range 400-963]; t1: 404 µmol/l [range 249-780]; t2: 400 µmol/l [range 260-815]; P <0.0001), insulin dose (t0: 1.3 IU/kg [range 0.5-4.6]; t0: 0.5 IU/kg [range 0-2.3]; t2: 0.4 IU/kg [range 0-2.1]; P <0.0001) and IRI (t0: 800 µmolIU/kgl [range 257-2700]; t1: 300 µmolIU/kgl [range 0-1498]; t2: 250 µmolIU/kgl [range 0-1498]; P <0.0001) decreased significantly during cabergoline treatment. Eight cats achieved diabetic remission between months 1 and 6 of cabergoline treatment (median time to achieve remission: 3 months [range 1-6]). Three cats experienced asymptomatic hypoglycemia.

Conclusions and relevance: Cabergoline was effective in normalizing IGF-1 concentration in 26% of cats. Cabergoline improved diabetes control and was associated with remission of DM in 35% of cases. Cabergoline could be a treatment option for cats with HST and DM, especially in those cases with a relatively small pituitary tumor.

Keywords: Acromegaly; cabergoline; diabetes mellitus remission; insulin-like growth factor 1.

PubMed Disclaimer

Conflict of interest statement

The authors declared no conflicts of interest with respect to the authorship, research and publication of this article.

Figures

Figure 1
Figure 1
Serum insulin-like growth factor 1 (IGF-1) concentrations before and during cabergoline treatment. *P <0.05. t0 = diagnosis of hypersomatotropism and start of cabergoline treatment; t1 = month 3 of cabergoline treatment; t2 = month 6 of cabergoline treatment
Figure 2
Figure 2
Serum fructosamine concentrations before and during cabergoline treatment. ***P <0.001. t0 = diagnosis of hypersomatotropism and start of cabergoline treatment; t1 = month 3 of cabergoline treatment; t2 = month 6 of cabergoline treatment
Figure 3
Figure 3
Individual insulin dose (IU/kg q12h) before and during cabergoline treatment. ***P <0.001. t0 = diagnosis of hypersomatotropism and start of cabergoline treatment; t1 = month 3 of cabergoline treatment; t2 = month 6 of cabergoline treatment
Figure 4
Figure 4
Insulin Resistance Index (fructosamine q12h insulin dose [U/kg]) before and during cabergoline treatment. ***P <0.001. t0 = diagnosis of hypersomatotropism and start of cabergoline treatment; t1 = month 3 of cabergoline treatment; t2 = month 6 of cabergoline treatment
See this image and copyright information in PMC

References

    1. Rijnberk A, Kooistra HS, Mol JA. Endocrine diseases in dogs and cats: similarities and differences with endocrine diseases in humans. Growth Horm IGF Res 2003; 13 Suppl: S158–164. - PubMed
    1. Scudder CJ, Mirczuk SM, Richardson KM, et al.. Pituitary pathology and gene expression in acromegalic cats. J Endocr Soc 2018; 3: 181–200. - PMC - PubMed
    1. Niessen SJ, Forcada Y, Mantis P, et al.. Studying cat (Felis catus) diabetes: beware of the acromegalic imposter. PLoS One 2015; 10: e0127794. DOI: 10.1371/journal.pone.0127794. - PMC - PubMed
    1. Schaefer S, Kooistra HS, Riond B, et al.. Evaluation of insulin-like growth factor-1, total thyroxine, feline pancreasspecific lipase and urinary corticoid-to-creatinine ratio in cats with diabetes mellitus in Switzerland and the Netherlands. J Feline Med Surg 2017; 19: 888–896. - PMC - PubMed
    1. Colao AM, Grasso LFS, Giustina A, et al.. Acromegaly. Nat Rev Dis Primers 2019; 5: 20. DOI: 10.1038/s41572-019-0071-6. - PubMed